Financing channel feed

Af­ter bring­ing his to­tal raise for Odyssey to $386M, Gary Glick is ready to start ink­ing deals. Just watch

3 years ago

Now with pos­i­tive PhI da­ta, DICE goes af­ter pub­lic of­fer­ing in search of $250M

3 years ago

With help from Lu­l­ule­mon founder’s ven­ture phil­an­thropy, Vi­ta adds sec­ond mus­cu­lar dy­s­tro­phy in­di­ca­tion to line­up

3 years ago
R&D

Roy­al­ty Phar­ma bets Mer­ck­'s schiz­o­phre­nia drug can go where Pfiz­er, Take­da and Lund­beck­'s couldn’t

3 years ago
Deals
Pharma

Michael Ehlers and Ro­mesh Sub­ra­man­ian launch biotech with $50M, sea squirt-in­spired RNA-edit­ing tech

3 years ago
Startups

A year af­ter de­but­ing with $500M, Bob Nelsen's Re­al­ly Big Neu­ro­science Com­pa­ny rais­es a re­al­ly not-as-big Se­ries B

3 years ago

Af­ter two CRLs, FDA ap­proves scPhar­ma­ceu­ti­cal­s' drug-de­vice as biotech nabs $100M to fund launch

3 years ago
FDA+

A liv­er dis­ease up­start with some glob­al con­nec­tions and a new R&D strat­e­gy reaps a $30M launch round

3 years ago
R&D

On­colyt­ic virus ex­perts at Replimune re­load with $200M loan as biotech col­lects clin­i­cal da­ta

3 years ago

Armed with $125M, Nest­ed Ther­a­peu­tics de­buts with plan to jump­start next-gen pre­ci­sion on­col­o­gy ef­forts

3 years ago
Startups

Cal­i­for­nia dream­in': Red Tree VC shop takes Boston fund­s' spin­out ap­proach to West Coast

3 years ago
Startups

Af­ter Covid set­back, Val­ne­va lines up $100M for Pfiz­er-al­lied Ly­me dis­ease PhI­II

3 years ago
Pharma
Coronavirus

A dozen years in the mak­ing, a UC Berke­ley spin­out nabs funds to take on the eye

3 years ago
Startups

Amy­lyx snatched the land­mark ap­proval for its ALS drug. Now it’s seek­ing cash to foot the launch bill

3 years ago

Look­ing to push CAR-T in sol­id tu­mors, Bay Area biotech goes pub­lic in SPAC flip — with slight name change

3 years ago
Deals

Tiny Ver­gent seals mod­est Se­ries B in pur­suit of can­cer imag­ing agent

3 years ago
R&D

A year and a half af­ter Cel­lar­i­ty raised $123M, the Flag­ship biotech is back — and it's ready to pick out can­di­dates

3 years ago
Startups

George Church, Wyss sci­en­tists and North­pond chal­lenge con­ven­tion­al RNA man­u­fac­tur­ing with new biotech

3 years ago
People
Cell/Gene Tx

Re­cent­ly out-of-stealth neu­ro­science out­fit un­veils cash raise, more de­tails on Lil­ly, North­west­ern pro­grams

3 years ago
R&D

Chi­na’s Yisheng­Bio is go­ing to Nas­daq, mak­ing the tran­si­tion via $230M SPAC ma­neu­ver

3 years ago
China

'Struc­ture, beau­ty and clar­i­ty': With seed fi­nanc­ing, Kalei­do­scope aims to syn­chro­nize R&D teams

3 years ago
Startups

Bris­tol My­ers got the first TYK2 ap­proval. Fra­zier’s new biotech Su­do hopes to get many more

3 years ago
Startups

A new ADC biotech looks to re­vive se­cre­tive plat­form, se­cures Big VC back­ing

3 years ago
Startups

George Church’s wool­ly mam­moth re­vival biotech Colos­sal spins out com­pu­ta­tion­al bio out­fit

3 years ago
Startups
First page Previous page 46474849505152 Next page Last page
A service from the Financial Times